Jill M. Quigley bought stock once, on Mar 3, 2020

Jill M. Quigley, J.D. is a corporate director and biotechnology executive who serves on the board of Terns Pharmaceuticals, Inc. (TERN), where she has been a director since December 2020 and is Chair of the Audit Committee.( She has filed insider trading reports with the U.S. Securities and Exchange Commission in connection with her equity holdings and transactions as a director of Terns Pharmaceuticals.( In addition to her role at Terns, Quigley serves on the board of Chemomab Therapeutics Ltd., a publicly traded biotechnology company, and has held senior advisory responsibilities and interim strategic leadership roles at Terns.(

Quigley’s career spans senior leadership positions across multiple biopharmaceutical companies, including serving as Chief Executive Officer of Genuiti Therapeutics, Inc., a private biotechnology company, since September 2023,( and previously as Chief Operating Officer of Passage Bio, Inc., a publicly traded gene therapy company, from November 2018 to December 2021.( Before Passage Bio, she was Interim Chief Executive Officer and General Counsel of Nutrinia, Inc., and earlier held legal and corporate roles at Shire plc, NPS Pharmaceuticals, Pharmasset, Integra LifeSciences, and the law firm Dechert LLP.( Quigley holds a B.A. in Communications, Legal Institutions, Economics & Government (CLEG) from American University and a J.D. from Rutgers School of Law.(

Written by Perplexity from public sources.